A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 4 more changesShow less
    • Study completion date changed from estimate of Sep 24, 2026 to Sep 30, 2026
    • Eligibility criteria expanded, about 24 words
    • Secondary endpoints: details revised at 3 of 24 entries
    • Site details revised at 3 of 70 sites
  2. Enrollment increased: 360 → 447 participants
    • Primary completion date changed from estimate of Jun 1, 2026 to May 29, 2026
    v22
  3. Primary completion moved earlier from Aug 10, 2026 to Jun 1, 2026
    • Study completion moved earlier from Nov 30, 2026 to Sep 24, 2026
    • Interventions: CT-388 (Drug), Placebo (Drug) to Enicepatide (Drug), Placebo (Drug)
    • Study title expanded, about 1 word
    v21
  4. Re-verified, no change to tracked fieldsv20
  5. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 85 to 70
    v19
Show 17 earlier versionsHide 17 earlier versions
  1. Study sites: 84 to 85v18
  2. Study sites: 79 to 84v17
  3. Study sites: 67 to 79v16
  4. Study sites: 58 to 67v15
  5. Study sites: 57 to 58v14
  6. Primary endpoints revised (2)v13 Show 5 more changesShow less
    • Study sites: 43 to 57
    • Primary completion date: May 31, 2026 to Aug 10, 2026
    • Study completion date: May 31, 2026 to Nov 30, 2026
    • Eligibility criteria expanded, about 92 words
    • Secondary endpoints: 22 to 24
  7. Study sites: 41 to 43v12
  8. Study sites: 38 to 41v11
  9. Study sites: 33 to 38v10
  10. Study sites: 32 to 33v9
  11. Study sites: 30 to 32v8
  12. Study sites: 26 to 30v7
  13. Site details revised at 1 of 26 sitesv6
  14. Study sites: 12 to 26
    • Start date changed from estimate of Nov 30, 2024 to Nov 21, 2024
    v5
  15. Start date: Oct 30, 2024 to Nov 30, 2024
    • Study sites: 3 to 12
    v4
  16. Study sites: 1 to 3v3
  17. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Carmot Therapeutics, Inc.
3 trials monitored
See all monitored trials
Diabetes
5,101 trials monitored
See 233 trials at risk
Obesity
3,888 trials monitored
See 157 trials at risk
Type 2 Diabetes
2,236 trials monitored
See 113 trials at risk
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).
Trial Details
NCT Number NCT06628362
Lead Sponsor Carmot Therapeutics, Inc.
Collaborators: Hoffmann-La Roche
Conditions
(from sponsor)		 Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
Related terms Diabetes Mellitus, Type 2, Obesity, Overweight
Enrollment 447 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov